Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Intranet
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Approval Alert: European Commission Approves MSD’s Keytruda® (pembrolizumab) Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer (NSCLC)

Mar 28, 2024

Merck (MSD) announced that the European Commission approved Keytruda® (pembrolizumab) in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer (NSCLC).  The announcement comes after positive results over several measures from the Phase 3 KEYNOTE-671 clinical trial.

The news follows US FDA approval for the same indication reported in 2023.